Corvus Pharmaceuticals Inc Stock
A very strong showing by Corvus Pharmaceuticals Inc today, with an increase of €0.40 (3.300%) compared to yesterday's price.
We see a rather positive sentiment for Corvus Pharmaceuticals Inc with 8 Buy predictions and 1 Sell predictions.
With a target price of 27 € there is potential for a 118.54% increase which would mean more than doubling the current price of 12.36 € for Corvus Pharmaceuticals Inc.
Our community identified positive and negative aspects for Corvus Pharmaceuticals Inc stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corvus Pharmaceuticals Inc stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | 3.300% | 1.014% | -19.946% | 373.663% | 93.215% | 1139.378% | 363.566% |
| Heron Therapeutics Inc. | -1.020% | -3.745% | -28.857% | -64.610% | -37.702% | -60.343% | -95.078% |
| Evolus Inc | 2.310% | 0.000% | -28.807% | -63.958% | -36.514% | -53.557% | -67.664% |
| Sangamo Therapeutics Inc. | -15.030% | -8.790% | -19.538% | -56.547% | -25.243% | -82.980% | -97.492% |
Comments
Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $32.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
News
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic
